Lisata Therapeutics, Inc. (LSTA) Q1 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Welcome to the La Sada Therapeutics first quarter 2025 financial results and business update conference call. Currently, all participants are in listen-only mode. Following management's prepared remarks, we will hold a Q&A session. To ask a question at that time, please press star 11 on your telephone. You will then hear an automated message advising your hand is raised. As a reminder, this call is being recorded today, Thursday, May 8, 2025. I will now turn the call over to John Mendito, Vice President of Investor Relations and Corporate Communications at La Sada. Please go ahead, sir. Thank you, operator, and good afternoon, everyone. Welcome to La Sada's first quarter 2025 conference call to discuss our financial results and to provide a business update. Joining me today from our management team are Dr. David Mazzo, President and Chief Executive Officer, Dr. Kristen Buck, Executive Vice President of Research and Development and Chief Medical Officer, and James Nisko, Senior Vice President of Finance and Treasury and Chief Accounting Officer. Shortly before this call, we issued a press release announcing our first quarter 2025 financial results, which is all under the Investors and News section of the company website, along with a webcast replay of this call. If you have not received this news release or would like to be added to the company's email distribution list, please subscribe to the email alerts on the company website or email me at jmendito at lasada.com. to be added to the list. Before we begin, I remind you that comments made by management during this conference call will contain forward-looking statements that involve risks and entities regarding the operations and future results of this audit. I encourage you to review the company's filings with the S...